283 related articles for article (PubMed ID: 22209563)
1. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
Hagihara M; Kuti JL; Nicolau DP
Diagn Microbiol Infect Dis; 2012 Mar; 72(3):258-62. PubMed ID: 22209563
[TBL] [Abstract][Full Text] [Related]
2. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
[TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
[TBL] [Abstract][Full Text] [Related]
4. In vitro sensitivity of Acinetobacter baumannii and Pseudomonas aeruginosa to carbapenems among intensive care unit patients.
Guzek A; Korzeniewski K; Nitsch-Osuch A; Rybicki Z; Prokop E
Adv Exp Med Biol; 2013; 788():109-16. PubMed ID: 23835967
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
[TBL] [Abstract][Full Text] [Related]
6. The laboratory diagnosis of Pseudomonas aeruginosa that produce metallo-β-lactamases in a Dutch tertiary care centre.
van der Bij AK; Mol M; van Westreenen M; Goessens WH; Pitout JD
Scand J Infect Dis; 2011 Aug; 43(8):596-602. PubMed ID: 21506891
[TBL] [Abstract][Full Text] [Related]
7. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
Turner PJ
Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
[TBL] [Abstract][Full Text] [Related]
8. Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.
Micaëlo M; Brossier F; Bréchot N; Luyt CE; Lu Q; Monsel A; Jarlier V; Aubry A
Med Mal Infect; 2018 Aug; 48(5):365-371. PubMed ID: 29628176
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
Castanheira M; Jones RN; Livermore DM
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):426-33. PubMed ID: 19249180
[TBL] [Abstract][Full Text] [Related]
10. [Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study].
Gimeno C; Cantón R; García A; Gobernado M;
Rev Esp Quimioter; 2010 Sep; 23(3):144-52. PubMed ID: 20844845
[TBL] [Abstract][Full Text] [Related]
11. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff DA; Nicolau DP
Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
[TBL] [Abstract][Full Text] [Related]
12. Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status.
Esterly JS; Qi C; Malczynski M; Scheetz MH
Pharmacotherapy; 2010 Apr; 30(4):354-60. PubMed ID: 20334455
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of doripenem.
Sahm D
Clin Infect Dis; 2009 Aug; 49 Suppl 1():S11-6. PubMed ID: 19619017
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
[TBL] [Abstract][Full Text] [Related]
15. [Shall we report the carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii strains detected by BD Phoenix system?].
Oğünç D; Ongüt G; Ozen NS; Baysan BO; Günseren F; Dağlar D; Demirbakan H; Gültekin M
Mikrobiyol Bul; 2010 Apr; 44(2):197-202. PubMed ID: 20549953
[TBL] [Abstract][Full Text] [Related]
16. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
[TBL] [Abstract][Full Text] [Related]
17. Doripenem vs meropenem against Pseudomonas and Acinetobacter.
Goyal K; Gautam V; Ray P
Indian J Med Microbiol; 2012; 30(3):350-1. PubMed ID: 22885206
[TBL] [Abstract][Full Text] [Related]
18. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
Eagye KJ; Banevicius MA; Nicolau DP
Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
[TBL] [Abstract][Full Text] [Related]
19. In vitro antibacterial activities of doripenem, imipenem, and meropenem against recent Streptococcus pneumoniae isolates.
Baek JY; Ko KS; Kang CI; Song JH; Peck KR
Diagn Microbiol Infect Dis; 2011 Nov; 71(3):297-300. PubMed ID: 21855246
[TBL] [Abstract][Full Text] [Related]
20. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
